The company operates a composite textile mill producing cotton and blended yarns and fabrics, while also managing and leasing 'The Ruby,' a large-scale commercial office tower in Mumbai.
The company lacks a moat in textiles, evidenced by low ROCE (6.4%) and volatile margins. While 'The Ruby' tower is a high-quality real estate asset with location-based advantages, it functions more as a property holding than a durable competitive advantage for the textile business.
Capital has been heavily directed toward real estate development and solar power initiatives. While real estate provides rental income, the overall return on capital remains mediocre, and the company recently had to return a 101 crore deposit due to a buyer's legal disputes.
The investment collapsed as the textile division's mediocre returns further deteriorated, failing to cover its cost of capital while management remained distracted by non-core real estate and solar ventures. The 'Ruby Tower' rental income, once seen as a safety net, became a trap as legal entanglements and title deed issues prevented liquidity when it was most needed. Ultimately, the combination of high promoter pay, related-party transactions, and poor capital discipline eroded the book value, leaving shareholders with a stagnant, asset-heavy business that the market finally re-rated to a deep discount.
RichFakir rates Ruby Mills Ltd's business quality as mediocre — 42/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Ruby Mills Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Ruby Mills Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Ruby Mills Ltd's fair value is about ₹187 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →